Zhengye Biotechnology Holding (ZYBT) Operating Leases (2025)
Zhengye Biotechnology Holding's (ZYBT) quarterly Operating Leases came in at $46104.6 in Q4 2025.
Powered by 
Analysis
Zhengye Biotechnology Holding (ZYBT) Operating Leases (2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Operating Leases for 1 consecutive years, with $46104.6 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Operating Leases changed N/A year-over-year to $46104.6 in Q4 2025; TTM through Dec 2025 was $46104.6, a N/A change from a year earlier, with the FY2025 full-year figure at $47000.0, changed N/A from the prior year.
- Operating Leases was $46104.6 for Q4 2025 at Zhengye Biotechnology Holding.
- Over five years, Operating Leases peaked at $46104.6 in Q4 2025 and troughed at $46104.6 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.54 Bn | 40.34 Bn | 779.09 Mn |
| 2 | Zoetis | 30.61 Bn | 28.94 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.50 Bn | 1.42 Bn | 134.40 Mn |
| 5 | Immucell | 89.92 Mn | 81.06 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 75.05 Mn | 67.96 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |